

X-ray Structure Analyses and Biological Evaluations of a New Cd(II) Complex with S-Triazine Based Ligand

Kholood A. Dahlous ^{1,*}, Atallah A. M. Alotaibi ², Necmi Dege ³, Ayman El-Faham ^{2,*}, Saied M. Soliman ^{2,*} and Heba M. Refaat ^{2,*}

¹ Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia

² Department of Chemistry, Faculty of Science, Alexandria University, P.O. Box 426, Alexandria 21321, Egypt; atallah1415@gmail.com

³ Department of Physics, Faculty of Arts and Sciences, Ondokuz Mayıs University, Samsun 55139, Turkey; necmid@omu.edu.tr

* Correspondence: kdahloos@ksu.edu.sa (K.A.D.); aymanel_faham@hotmail.com (A.E.-F.); saied1soliman@yahoo.com (S.M.S.); hebarefaat212@yahoo.com (H.M.R.)

Chemicals and instrumentations

Chemicals were purchased from Sigma-Aldrich Company (Chemie GmbH, 82024 Taufkirchen, Germany). CHN analyses were performed using Perkin Elmer 2400 Elemental Analyzer (PerkinElmer, Inc. 940 Winter Street, Waltham, MA, USA). The Cd content was determined using Shimadzu atomic absorption spectrophotometer (AA-7000 series, Shimadzu, Ltd, Japan). An Alpha Bruker spectrophotometer (Billerica, Massachusetts, USA) was used to measure the FTIR spectra in KBr pellets (**Figure S1**).

X-ray structure measurement details

Crystals of the target complex were collected from the reaction mixture by filtration, then suitable crystal for X-Ray diffraction analysis was selected and data collection was performed on a Bruker diffractometer equipped with a graphite-monochromatic Mo-K α radiation at 296 K. The structures were solved by direct methods using SHELXT-2018 [52] and refined by full-matrix least-squares methods on F² using SHELXL-2018 [53] from within the WINGX [54] suite of software. Bruker APEX2 [55] was used for data collection, while molecular diagrams were created using MERCURY [56]. All non-hydrogen atoms were localized on difference Fourier maps and refined in subsequent full-matrix least-squares calculations including anisotropic atomic displacement parameters. All hydrogen atoms were refined with the riding model implemented in SHELX. Absorption corrections were performed by SADABS [57]. Hirshfeld calculations were performed using Crystal Explorer 17.5 program [58].




Figure S1. FTIR spectra of $[\text{Cd}(\text{BPMT})\text{Br}_2]$ complex.





Figure S2. FTIR spectra of **BPMT**.

Method S1: Synthesis of BPMT [51,52]

The ligand (**BPMT**) was synthesized following the method shown in **Scheme S1**. At room temperature, 2,4-dihydrazinyl-6-methoxy-1,3,5-triazine (10 mmol in 20 mL DMF) was mixed with acetylacetone (25 mmol) followed by addition of triethylamine (8 mmol in 10 mL DMF) with stirring then refluxed for 6 h. After completion of the reaction, the mixture is left to cool till room temperature, and then ice-cold water was added (100 mL). The reaction mixture was kept at 0°C for

2 h, white solid powder of **BPMT** is precipitated. The product is filtered, washed with cold water (3 x 20 mL), and then dried.

Yield; C₁₄N₇H₁₇O (**BPMT**) 86%; mp 175-176 °C. Anal. Calc. C, 56.18; H, 5.72; N, 32.76%. Found: C, 56.16; H, 5.74; N, 32.77%; IR (KBr, cm⁻¹): 3041, 2978, 2926, 1593, 1555. ¹H NMR (CDCl₃) δ: 2.30 (s, 6H, 2CH₃), 2.72 (s, 6H, 2CH₃), 4.12 (s, 3H, OCH₃), 6.05 (s, 2H, CH) ppm; ¹³C NMR (CDCl₃): δ 13.8, 17.8, 55.7, 111.9, 144.4, 153.3, 164.8, 172.3 ppm.



Scheme S1. Synthesis of the ligand (**BPMT**).

Method S2: Antimicrobial studies [59]

a) Tested pathogenic microbes

The antibacterial activity of the free ligand and its Cd(II) complexes were evaluated against two Gram-positive bacteria ((*S. aureus* (ATCC 25923) and *B. subtilis* (RCMB015(1)NRR LB-543)), two Gram-negative bacteria ((*E. coli* (ATCC 25922) and *P. vulgaris* (RCMB 004(1)ATCC 13315)) and two fungi ((*A. fumigatus* (RCMB 002008) and *C. albicans* (RCMB 005003(1) ATCC 10231)). Gentamycin was used as standard antibacterial agent. The samples maintained in Brain heart infusion (BHI) at 20 °C; 300 mL of each stock-culture was added to 3 mL of BHI broth. Overnight cultures were kept for 24 h at 37 °C ± 1 °C and the purity of cultures was checked after 24 h of incubation. After 24 h of incubation, bacterial suspension was diluted with sterile physiological solution, for the diffusion and indirect bioautographic tests, to 10⁸ CFU/mL (turbidity = McFarland barium sulfate standard 0.5). In case of fungi *A. fumigatus* (RCMB 002008) and *C. albicans* (RCMB 005003(1) ATCC 10231), the used medium in antagonistic activity against tested fungi is Potato Dextrose Agar, where Fluconazole was used standard antifungal agent.

b) Agar well diffusion method

Synthetic compounds were prepared at concentration 10 mg/mL dissolved in DMSO as stock solutions. Preparation of sterilized Mueller Hinton agar plates seeded with tested pathogenic

bacteria occurred. The wells are done by sterilized cork borer in size 6 mm and hence 200 µg of the synthetic compound was poured in each well comparably with DMSO as control. The plates were incubated at 37 °C for 24 h. after incubation period; antimicrobial activity was determined by inhibition zones.

c) Minimum Inhibitory Concentration (MIC)

Different dilutions of the compounds are inoculated with tested pathogenic microbes. After incubation period of 96 well microplate, the results are measured using microplate reader. To determine at what level the MIC endpoint is established; subculture of test samples at different concentrations occurred in nutrient agar plates.

Method S3 Evaluation of Cytotoxic activity [60]

Cell line Propagation

The cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 1% L-glutamine, HEPES buffer and 50 µg/mL Gentamycin. All cells were maintained at 37 °C in a humidified atmosphere with 5% CO₂ and were subcultured two times a week.

Cytotoxicity evaluation using viability assay

For cytotoxicity assay, the cells were seeded in 96-well plate at a cell concentration of 1×10^4 cells per well in 100 µL of growth medium. Fresh medium containing different concentrations of the test sample was added after 24 h of seeding. Serial two-fold dilutions of the tested chemical compound were added to confluent cell monolayers dispensed into 96-well, flat-bottomed microtiter plates (Falcon, NJ, USA) using a multichannel pipette. The microtiter plates were incubated at 37°C in a humidified incubator with 5% CO₂ for a period of 24 h. Three wells were used for each concentration of the test sample. Control cells were incubated without test sample and with or without DMSO. The little percentage of DMSO present in the wells (maximal 0.1%) was found not to affect the experiment. After incubation of the cells for at 37 °C, for 24 h, the viable cells yield was determined by the MTT test. Briefly, the media was removed from the 96 well plate and replaced with 100 µL of fresh culture DMEM medium without phenol red then 10 µL of the 12 mM MTT stock solution (5 mg of MTT in 1 mL of PBS) to each well including the untreated controls. The 96 well plates were then incubated at 37 °C and 5% CO₂ for 4 hours. An 85 µL aliquot of the media was removed from

the wells, and 50 μ L of DMSO was added to each well and mixed thoroughly with the pipette and incubated at 37°C for 10 min. Then, the optical density was measured at 590 nm with the microplate reader (SunRise, TECAN, Inc, USA) to determine the number of viable cells and the percentage of viability was calculated as $[(OD_t/OD_c)] \times 100\%$ where OD_t is the mean optical density of wells treated with the tested sample and OD_c is the mean optical density of untreated cells. The relation between surviving cells and drug concentration is plotted to get the survival curve of each tumor cell line after treatment with the specified compound. The 50% inhibitory concentration (IC_{50}), the concentration required to cause toxic effects in 50% of intact cells, was estimated from graphic plots of the dose response curve for each conc. using Graphpad Prism software (San Diego, CA. USA).

Table S1. Evaluation of cytotoxicity of $[Cd(BPMT)Br_2]$ against A-549 cell line.

Conc. (μ g/mL)	Viability %	Inhibitory %	S.D. (\pm)
500	1.96	98.04	0.48
250	5.84	94.16	0.28
125	11.23	88.77	0.69
62.5	19.59	80.41	1.71
31.25	36.54	63.46	2.08
15.6	53.27	46.73	2.15
7.8	75.49	24.51	1.47
3.9	87.81	12.19	0.93
0	100	0	

Table S2. Evaluation of cytotoxicity of **BPMT** against A-549 cell line.

Conc. (μ g/mL)	Viability %	Inhibitory %	S.D. (\pm)
500	28.39	71.61	1.97
250	70.86	29.14	3.12
125	89.43	10.57	2.09
62.5	98.70	1.3	0.68
31.25	100	0	

15.6	100	0
7.8	100	0
3.9	100	0
0	100	0

References

- [59] CLSI; Clinical and Laboratory Standards Institute, 2012, Twentieth informational supplement. M100-S22. Wayne: PA.
- [60] Mosmann, T. (1983): Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods; 65: 55-63.